Kodiak Sciences Inc.
Kodiak Sciences Inc. (KOD): 7 pipeline candidates · 3 upcoming catalysts · ~13 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.8 months
D/E 1.73 · 0% dilution
Lead: Phase 3
7 candidates
3 upcoming, next in ~409d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Kodiak Sciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.3B
Cash
$169.5M
Quarterly Burn
$40.0M
Runway
12.8 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ksi-101 | Phase 3 |
| ksi-102 | Phase 3 |
| ksi-103 | Phase 3 |
| ksi-501 | Phase 3 |
| tabirafusp tedromer | Phase 3 |
| tarcocimab | Phase 3 |
| tarcocimab tedromer | Phase 3 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$2.14B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 19,919,186 | $759.3M |
| blackrock, inc. | 3,935,302 | $150.0M |
| vanguard capital management llc | 3,434,152 | $130.9M |
| janus henderson group plc | 2,650,914 | $101.1M |
| state street corp | 2,250,920 | $85.8M |
| braidwell lp | 1,818,665 | $69.3M |
| goldman sachs group inc | 1,739,003 | $66.3M |
| rtw investments, lp | 1,487,934 | $56.7M |
| ikarian capital, llc | 1,365,795 | $52.1M |
| iconiq capital, llc | 1,266,563 | $48.3M |
Showing top 10 of 189 institutional holders of Kodiak Sciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kodiak Sciences Inc.'s pipeline?
Kodiak Sciences Inc. (KOD) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kodiak Sciences Inc.'s lead drug candidate?
Kodiak Sciences Inc.'s most advanced tracked candidate is ksi-101 (Phase 3) for Macular Edema Secondary to Inflammation.
What is Kodiak Sciences Inc.'s next catalyst?
Kodiak Sciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy an" — expected August 1, 2027.
What is Kodiak Sciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kodiak Sciences Inc. has approximately 12.8 months of cash runway.
What is Kodiak Sciences Inc.'s market capitalization?
Kodiak Sciences Inc.'s market capitalization is approximately $2.3B.
Get the full picture on Kodiak Sciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.